Vertex Pharmaceuticals upgraded to Outperform at SVB Securities
The Fly

Vertex Pharmaceuticals upgraded to Outperform at SVB Securities

SVB Securities analyst David Risinger upgraded Vertex Pharmaceuticals to Outperform from Market Perform with a price target of $374, up from $265, arguing that the company’s earnings growth and durability are "underappreciated."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on VRTX:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App